Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising ...

Conservative podcast host Liz Wheeler, who was part of the influencer group during “Epstein Files: Phase 1,” told SiriusXM’s ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

For the first time, scientists have 3-D printed objects within living cells, including a 10-micrometer long elephant and tiny “barcodes” that could help track individual cells. Remarkably, many of the ...

Fred Hutch researchers have created a gene-expression map of glial cells of the tiny worm, C. elegans, adding the missing ...

A fertilized egg somehow manages to build skin, brain, and blood cells within days. But how? New tech called LoxCode is ...

A previously unknown structure discovered in our cells could pave the way toward new treatments for various genetic disorders ...

Cancer cells can acquire energy-generating structures called mitochondria from nearby nerve cells, which seems to aid their ...

Blue Label Telecoms, the majority shareholder of Cell C, is mulling the possible listing of the mobile operator on the Johannesburg Stock Exchange (JSE) as it restructures its business.

Blue Label is exploring a potential restructure of the group which may facilitate separation and potential future listing of Cell C on the Prime Segment of the Main Board of the Johannesburg Stock ...